Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer
- Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic
- Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies
Oxford, UK, 16 February 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, today announces the appointment of Dr. Michelle Morrow as Chief Scientific Officer (CSO) as of 23 February 2026.
